Abstract:Metabolic disorders associated with obesity and cardiometabolic disorders are worldwide epidemic. Among the different environmental factors, the gut microbiota is now considered as a key player interfering with energy metabolism and host susceptibility to several non-communicable diseases. Among the next-generation beneficial microbes that have been identified, Akkermansia muciniphila is a promising candidate. Indeed, A. muciniphila is inversely associated with obesity, diabetes, cardiometabolic diseases and low-grade inflammation. Besides the numerous correlations observed, a large body of evidence has demonstrated the causal beneficial impact of this bacterium in a variety of preclinical models. Translating these exciting observations to human would be the next logic step and it now appears that several obstacles that would prevent the use of A. muciniphila administration in humans have been overcome. Moreover, several lines of evidence indicate that pasteurization of A. muciniphila not only increases its stability but more importantly increases its efficacy. This strongly positions A. muciniphila in the forefront of next-generation candidates for developing novel food or pharma supplements with beneficial effects. Finally, a specific protein present on the outer membrane of A. muciniphila, termed Amuc_1100, could be strong candidate for future drug development. In conclusion, as plants and its related knowledge, known as pharmacognosy, have been the source for designing drugs over the last century, we propose that microbes and microbiomegnosy, or knowledge of our gut microbiome, can become a novel source of future therapies.

Research Progress on the Next‐generation Probiotic Akkermansia Muciniphila in the Intestine

A Review of a Potential and Promising Probiotic Candidate—akkermansia Muciniphila

Function and therapeutic prospects of next-generation probiotic Akkermansia muciniphila in infectious diseases

Research Progress on Akkermansia Muciniphila in Human Intestine

Akkermansia muciniphila as a Next-Generation Probiotic in Modulating Human Metabolic Homeostasis and Disease Progression: A Role Mediated by Gut-Liver-Brain Axes?

Rational consideration of Akkermansia muciniphila targeting intestinal health: advantages and challenges

Health and Disease:Akkermansia Muciniphila,the Shining Star of the Gut Flora

Next-Generation Probiotics: Microflora Intervention to Human Diseases

The role of the probiotic Akkermansia muciniphila in brain functions: insights underpinning therapeutic potential

Akkermansia muciniphila in infectious disease: A new target for this next-generation probiotic?

Engineered Akkermansia muciniphila: A promising agent against diseases (Review)

Akkermansia muciniphila: A promising probiotic against inflammation and metabolic disorders

[Advances of Akkermansia muciniphila in regulating host functions]

Next-Generation Beneficial Microbes: The Case of Akkermansia muciniphila

The potential of Akkermansia muciniphila in inflammatory bowel disease

The Biofunction of Akkermansia Muciniphila in Intestinal-Related Diseases

Recent findings in Akkermansia muciniphila-regulated metabolism and its role in intestinal diseases

Akkermansia muciniphila: a potential candidate for ameliorating metabolic diseases

Akkermansia muciniphila : biology, microbial ecology, host interactions and therapeutic potential

A comprehensive update on the immunoregulatory mechanisms of Akkermansia muciniphila: insights into active ingredients, metabolites, and nutrient-driven modulation

Akkermansia muciniphila: a promising target for the therapy of metabolic syndrome and related diseases